MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
CareDx, Inc DSO Ratio 2011-2026 | CDNA
Annual DSO Ratio CareDx, Inc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.5 | 63.2 | 76.4 | 71.5 | 58.1 | 55.7 | 69.1 | 46.5 | 22.6 | 24.9 | 30.7 | 35.9 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 76.4 | 22.6 | 50.5 |
Quarterly DSO Ratio CareDx, Inc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.5 | 73.1 | 73.3 | - | 73.1 | 62.5 | 70.4 | - | 70.2 | 72 | 74.2 | - | 40.5 | 37 | 71.9 | - | 62.9 | 56.2 | 52.8 | - | 59.2 | 75.6 | 69.8 | 61.3 | 64.9 | 69.8 | 59.4 | 37.9 | 42 | 50 | 41.4 | 21.8 | 22.4 | 22.7 | 22.7 | 30.8 | 34.6 | 31.4 | 33.9 | 32.5 | 30.2 | 30.3 | 32 | 30.8 | 36.9 | 36.2 | 38.2 | 35.4 | 35.7 | 19 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 75.6 | 19 | 47.8 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
|
Biodesix
BDSX
|
41.7 | $ 15.21 | 3.54 % | $ 1.97 B |  USA |
 |
Bioventus
BVS
|
82.1 | $ 9.12 | 1.33 % | $ 608 M | USA |
 |
Biomerica
BMRA
|
57.7 | $ 2.12 | -0.47 % | $ 4.87 M | USA |
 |
Fulgent Genetics
FLGT
|
77.4 | $ 16.37 | 0.24 % | $ 495 M | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
80.5 | $ 75.01 | -0.96 % | $ 5.06 B | USA |
 |
Medpace Holdings
MEDP
|
50.4 | $ 460.9 | 0.87 % | $ 13.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
 |
Myriad Genetics
MYGN
|
52.3 | $ 4.77 | 2.36 % | $ 442 M | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 17.42 | -0.51 % | $ 390 M | USA |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
50.7 | - | -6.19 % | $ 10.5 M | USA |
 |
Pacific Biosciences of California
PACB
|
71.8 | $ 1.39 | -0.36 % | $ 417 M | USA |
 |
Co-Diagnostics
CODX
|
101 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
291 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
Precipio
PRPO
|
28.1 | $ 26.85 | -0.3 % | $ 34.8 M | USA |
 |
Personalis
PSNL
|
55.8 | $ 7.7 | 1.18 % | $ 456 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
RadNet
RDNT
|
34.5 | $ 60.0 | -2.83 % | $ 4.51 B | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 159.79 | 1.13 % | $ 7.92 B | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 165.38 | -0.95 % | $ 28.4 B | USA |
 |
Senseonics Holdings
SENS
|
10.3 | $ 6.74 | 1.81 % | $ 281 M | USA |
 |
Sotera Health Company
SHC
|
43.9 | $ 13.89 | 0.07 % | $ 3.94 B | USA |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
63.7 | $ 1.24 | -15.07 % | $ 6.75 M | USA |
 |
Neuronetics
STIM
|
48.7 | $ 1.49 | -7.19 % | $ 98.3 M | USA |
 |
Mettler-Toledo International
MTD
|
66.4 | $ 1 256.48 | 1.41 % | $ 25.9 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
53.1 | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
43.5 | $ 574.14 | -0.76 % | $ 46.2 B | USA |
 |
Illumina
ILMN
|
61.3 | $ 125.44 | 1.33 % | $ 19.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 101.04 | 0.68 % | $ 8.33 B |  Irlanda |
 |
Guardant Health
GH
|
46.1 | $ 85.0 | 0.05 % | $ 10.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
44.5 | $ 45.99 | 3.35 % | $ 2.75 B | USA |
 |
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
52.9 | $ 265.75 | 0.5 % | $ 22.1 B | USA |
 |
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K |  Israel |
 |
ENDRA Life Sciences
NDRA
|
7.11 | $ 3.36 | -3.45 % | $ 1.8 M | USA |
 |
NeoGenomics
NEO
|
77.7 | $ 8.05 | -0.62 % | $ 1.03 B | USA |
 |
Natera
NTRA
|
81.5 | $ 195.23 | -2.43 % | $ 19.2 B | USA |